Alto Neuroscience Inc. ANRO
i
Market datapartial · fetched 2026-11-12T14:59:07.809Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T14:58:09.124380067Z
FundamentalsAlpha Vantage · unavailable
Alto Neuroscience Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 25.72 | 137.9% | 18.7% | |||
| 25Δ | 26.39 | 133.0% | 17.3% | |||
| 30Δ | 27.06 | 128.2% | 16.0% | |||
| 35Δ | 27.74 | 123.3% | 14.7% | |||
| 40Δ | 28.41 | 118.5% | 13.4% | |||
| 45Δ | 33.71 | 194.4% | 18.3% | 29.08 | 113.6% | 12.0% |
| 50Δ | 32.29 | 166.6% | 13.7% | 29.76 | 108.8% | 10.7% |
| 55Δ | 30.86 | 138.8% | 9.0% | 30.43 | 103.9% | 9.4% |
| 60Δ | 29.61 | 122.1% | 6.0% | 31.11 | 99.1% | 8.1% |
| 65Δ | 28.62 | 122.1% | 5.2% | 31.78 | 94.2% | 6.8% |
| 70Δ | 27.64 | 122.1% | 4.4% | 32.45 | 89.4% | 5.4% |
| 75Δ | 26.66 | 122.1% | 3.6% | 33.13 | 84.5% | 4.1% |
| 80Δ | 25.68 | 122.0% | 2.9% | 33.80 | 79.7% | 2.8% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.72
- IV
- 137.9%
- B/E move
- 18.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 26.39
- IV
- 133.0%
- B/E move
- 17.3%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.06
- IV
- 128.2%
- B/E move
- 16.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.74
- IV
- 123.3%
- B/E move
- 14.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 28.41
- IV
- 118.5%
- B/E move
- 13.4%
45Δ
- Pseudo strike
- 33.71
- IV
- 194.4%
- B/E move
- 18.3%
- Pseudo strike
- 29.08
- IV
- 113.6%
- B/E move
- 12.0%
50Δ
- Pseudo strike
- 32.29
- IV
- 166.6%
- B/E move
- 13.7%
- Pseudo strike
- 29.76
- IV
- 108.8%
- B/E move
- 10.7%
55Δ
- Pseudo strike
- 30.86
- IV
- 138.8%
- B/E move
- 9.0%
- Pseudo strike
- 30.43
- IV
- 103.9%
- B/E move
- 9.4%
60Δ
- Pseudo strike
- 29.61
- IV
- 122.1%
- B/E move
- 6.0%
- Pseudo strike
- 31.11
- IV
- 99.1%
- B/E move
- 8.1%
65Δ
- Pseudo strike
- 28.62
- IV
- 122.1%
- B/E move
- 5.2%
- Pseudo strike
- 31.78
- IV
- 94.2%
- B/E move
- 6.8%
70Δ
- Pseudo strike
- 27.64
- IV
- 122.1%
- B/E move
- 4.4%
- Pseudo strike
- 32.45
- IV
- 89.4%
- B/E move
- 5.4%
75Δ
- Pseudo strike
- 26.66
- IV
- 122.1%
- B/E move
- 3.6%
- Pseudo strike
- 33.13
- IV
- 84.5%
- B/E move
- 4.1%
80Δ
- Pseudo strike
- 25.68
- IV
- 122.0%
- B/E move
- 2.9%
- Pseudo strike
- 33.80
- IV
- 79.7%
- B/E move
- 2.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 99.59% | |
| 109.09% | |
| 109.43% | |
| 114.01% | |
| 76.47% | |
| 80.79% | |
| 79.76% | |
| 78.25% | |
| 76.73% | |
| 76.12% | |
| 77.35% | |
| 78.96% | |
| 82.14% | |
| 76.28% | |
| 77.56% | |
| 80.83% | |
| 92.60% | |
| 94.72% | |
| 75.36% | |
| 79.45% | |
| 78.92% | |
| 83.81% | |
| 82.70% | |
| 82.31% | |
| 85.67% | |
| 95.41% | |
| 89.63% | |
| 98.59% | |
| 99.38% | |
| 107.36% | |
| 109.87% | |
| 121.17% | |
| 129.58% | |
| 150.65% | |
| 203.39% | |
| 83.59% | |
| 88.43% | |
| 88.41% | |
| 82.45% | |
| 86.91% | |
| 92.05% | |
| 89.80% | |
| 92.13% | |
| 84.05% | |
| 83.60% | |
| 87.58% |
Biotechnology
ANTX
Anthem, Inc., is a health benefits company in the United States. The company is headquartered in Indianapolis, Indiana.
More →ARCT
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
More →ARDX
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is…
More →ARGX
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The…
More →ARMP
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant…
More →ARQT
Description unavailable
More →